Key Highlights

  • Loss per share was USD 0.14 against an estimate of a USD 0.07 loss.
  • Net loss was USD 10.94 million, compared with USD 19.60 million.
  • Research and development expenses were USD 3.03 million, against USD 14.30 million.
  • The company signed a Merger agreement on August 16, 2026.

Fulcrum Therapeutics (NASDAQ:FULC) reported a third quarter 2026 loss per share of USD 0.14, against an estimate of a USD 0.07 loss and a USD 0.31 loss in the third quarter of 2025. The net loss was USD 10.94 million, compared with USD 19.60 million.

The loss from operations was USD 13.86 million, compared with USD 21.86 million, and other income, net, was USD 2.92 million, compared with USD 2.26 million.

Operating Expenses

Research and development expenses were USD 3.03 million, compared with USD 14.30 million, and general and administrative expenses were USD 8.44 million, compared with USD 7.56 million. Total operating expenses were USD 13.86 million, compared with USD 21.86 million.

The filing reports Impairment charges of USD 2.2 million for the quarter related to the write-down of the operating Lease right-of-use asset associated with the 26 Landsdowne Street facility, following a lease termination agreement with the landlord in September 2026. Restructuring charges were USD 0.2 million, compared with zero in the third quarter of 2025.

For the nine months ended September 30, 2026, the net loss was USD 56.01 million, compared with USD 54.55 million, and the loss per share was USD 0.73, compared with USD 0.87. Total operating expenses were USD 65.36 million, compared with USD 62.08 million, and other income, net, was USD 9.35 million, compared with USD 7.53 million.

Research and development expenses for the nine months were USD 29.56 million, compared with USD 40.69 million, and general and administrative expenses were USD 24.00 million, compared with USD 21.39 million. Impairment of long-lived Assets for the nine months was USD 7.25 million.

Restructuring and Merger Agreement

The filing states that on June 1, 2026 the company announced the discontinuation of its pociredir program for sickle cell disease and implemented a restructuring plan to significantly reduce operating expenses and preserve capital, reducing its workforce by approximately 85%, from 57 employees. In connection with the restructuring, the company ceased its active Research and Development activities and initiated a review of strategic alternatives.

That review resulted in an Agreement and Plan of Merger entered into on August 16, 2026 with Fusion Merger Sub I, Inc. and Fusion Merger Sub II, LLC, each a Subsidiary of the company, and Slate. The filing states that if the merger is completed, the company continues as the surviving corporation, changes its name to Slate Medicines, Inc., and that the management of Slate is anticipated to become the management of the combined corporation.

Balance Sheet

Cash and cash equivalents were USD 116.41 million, compared with USD 197.53 million at the prior Balance Sheet date, and marketable securities were USD 190.14 million, compared with USD 154.77 million. Total assets were USD 310.81 million, compared with USD 366.28 million, and total liabilities were USD 8.78 million, compared with USD 17.28 million.

The company states that its cash, cash equivalents and marketable securities are sufficient to fund its operating expenses and Capital expenditure requirements for at least 12 months from the date of issuance of the financial statements.

Fulcrum Therapeutics Q3 2026 Earnings: Key Takeaways

Fulcrum Therapeutics reported a third quarter 2026 loss per share of USD 0.14 and a net loss of USD 10.94 million. The company has signed a merger agreement dated August 16, 2026, and held USD 116.41 million of cash and cash equivalents and USD 190.14 million of marketable securities.